UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2104-2114

2011

Volltextzugriff (PDF)

Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer

Nature chemical biology, 2007-08, Vol.3 (8), p.498-507

2007

Volltextzugriff (PDF)

Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors

Journal of medicinal chemistry, 2022-10, Vol.65 (20), p.13784-13792

2022

Volltextzugriff (PDF)

Abstract 5161: Validation of drug candidates targeting dormant cancers in live cells as a key for successful translation into the clinic

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5161-5161

2020

Volltextzugriff (PDF)

Hsp90: the vulnerable chaperone

Drug Discovery Today, 2004-10, Vol.9 (20), p.881-888

2004

Volltextzugriff (PDF)

DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3

The Journal of clinical investigation, 2021-01, Vol.131 (1), p.1-18

2021

Volltextzugriff (PDF)

Abstract 3038: Implication of DYRK1B Kinase in ovarian cancers and utilization of DYRK1B Inhibitors as a novel therapeutic strategy for ovarian cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3038-3038

2019

Volltextzugriff (PDF)

A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects

Cancers, 2022-03, Vol.14 (6), p.1381

2022

Volltextzugriff (PDF)

Abstract 3195: DYRK1B inhibitors prevent pharmacologic quiescence and sensitize lung cancers to EGFR inhibitors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3195-3195

2017

Volltextzugriff (PDF)

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7672-7680

2009

Volltextzugriff (PDF)

Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14670-e14670

2019

Volltextzugriff (PDF)

Abstract 6269: A cell double barcoding system for quantitative evaluation of primary tumors & metastasis in animals: Uncovers clonal-specific anti-cancer drug effects

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.6269-6269

2022

Volltextzugriff (PDF)

How to design potent and selective DYRK1B inhibitors? Molecular modeling study

Journal of molecular modeling, 2019-02, Vol.25 (2), p.41-12, Article 41

2019

Volltextzugriff (PDF)

Cellular delivery of antisense oligonucleotides

European Journal of Pharmaceutics and Biopharmaceutics, 2000-07, Vol.50 (1), p.101-119

2000

Volltextzugriff (PDF)

Monitoring and analysis of antisense DNA by high-performance capillary gel electrophoresis

Journal of Chromatography A, 1994-03, Vol.663 (1), p.105-113

1994

Volltextzugriff (PDF)

Abstract 649: Mirk/dyrk1B kinase inactivation increases gemcitabine efficacy towards quiescent pancreatic cancer cells

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.649-649

2011

Volltextzugriff (PDF)

The Emergence and Evolution of the Universe

Journal of High Energy Physics, Gravitation and Cosmology, 2019, Vol.5 (3), p.884-898

2019

Volltextzugriff (PDF)

Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents

Cancer research (Chicago, Ill.), 2002-04, Vol.62 (7), p.2175-2183

2002

Volltextzugriff (PDF)

Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides

Nucleic acids research, 1998-12, Vol.26 (23), p.5310-5317

1998

Volltextzugriff (PDF)

Antisense RNA downregulation of bcl -xL protein expression

Vilenchik, Maria

2001

Volltextzugriff (PDF)

High-performance liquid chromatography and capillary gel electrophoresis as applied to antisense DNA

Journal of Chromatography A, 1993-05, Vol.638 (2), p.293-301

1993

Volltextzugriff (PDF)

Microtiter Cell-Based Assay for Detection of Agents that Alter Cellular Levels of Her2 and EGFR

Chemistry & biology, 2003-07, Vol.10 (7), p.629-634

2003

Volltextzugriff (PDF)

Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90

Chemistry & biology, 2004-06, Vol.11 (6), p.787-797

2004

Volltextzugriff (PDF)

Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition

Antisense & nucleic acid drug development, 2001-04, Vol.11 (2), p.87-97

2001

Volltextzugriff (PDF)

Delaying Satisfiability for Random 2SAT

Approximation, Randomization, and Combinatorial Optimization. Algorithms and Techniques, 2010, p.710-723

2010

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(22)

Publikationsform

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(14)
Humans
(11)
Animals
(6)
Biochemistry & Molecular Biology
(6)
Biological And Medical Sciences
(6)
Antineoplastic Agents - Pharmacology
(5)
Cell Line, Tumor
(5)
Medical Sciences
(4)
Neoplasms - Drug Therapy
(4)
Oncology
(4)
Pharmacology. Drug Treatments
(4)
Physical Sciences
(4)
Apoptosis
(3)
Cancer
(3)
Chemistry
(3)
Drug Design
(3)
Dyrk Kinases
(3)
Female
(3)
Mice
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells

Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer

Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors

Abstract 5161: Validation of drug candidates targeting dormant cancers in live cells as a key for successful translation into the clinic

Hsp90: the vulnerable chaperone

DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3

Abstract 3038: Implication of DYRK1B Kinase in ovarian cancers and utilization of DYRK1B Inhibitors as a novel therapeutic strategy for ovarian cancer

A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects

Abstract 3195: DYRK1B inhibitors prevent pharmacologic quiescence and sensitize lung cancers to EGFR inhibitors

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma

Abstract 6269: A cell double barcoding system for quantitative evaluation of primary tumors & metastasis in animals: Uncovers clonal-specific anti-cancer drug effects

How to design potent and selective DYRK1B inhibitors? Molecular modeling study

Cellular delivery of antisense oligonucleotides

Monitoring and analysis of antisense DNA by high-performance capillary gel electrophoresis

Abstract 649: Mirk/dyrk1B kinase inactivation increases gemcitabine efficacy towards quiescent pancreatic cancer cells

The Emergence and Evolution of the Universe

Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents

Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides

Antisense RNA downregulation of bcl -xL protein expression

High-performance liquid chromatography and capillary gel electrophoresis as applied to antisense DNA

Microtiter Cell-Based Assay for Detection of Agents that Alter Cellular Levels of Her2 and EGFR

Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90

Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition

Delaying Satisfiability for Random 2SAT

Suchergebnisse filtern